GlassScriptPhysician profile
Vanessa Meade
NPI 1649663659
$4,480.66
in general payments reported to CMS, 2019-2025
28 companies · $584 in 2025
The $584 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $993 · 2022: $1,193 · 2023: $893 · 2024: $818 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,207.21 | 2021-2025 | |
| Pfizer INC. | $663.31 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $398.04 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.18 | 2022-2025 | Jardiance |
| Abbott Laboratories | $354.62 | 2023-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $274.43 | 2021-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $206.32 | 2021-2025 | Lifevest |
| Amgen INC. | $165.07 | 2021-2023 | Repatha |
| Cvrx, INC. | $149.86 | 2022-2023 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $123.87 | 2021-2023 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $79.37 | 2022-2025 | Brilinta, Lokelma |
| Boston Scientific Corporation | $71.47 | 2022-2025 | Varithena Administration Pack, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $51.81 | 2021 | |
| Esperion Therapeutics, INC. | $50.31 | 2021 | |
| Atricure, INC. | $45.97 | 2024-2025 | Atriclip Laa Exclusion System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $33.73 | 2023 | Inpefa |
| Daiichi Sankyo INC. | $28.63 | 2021-2022 | |
| Altathera Pharmaceuticals LLC | $24.12 | 2023 | Sotalol Hydrochloride |
| Smith+Nephew, INC. | $22.12 | 2025 | Pico 7 |
| Heartflow, INC. | $19.75 | 2024 | |
| Silk Road Medical, INC. | $18.28 | 2022 | |
| United Therapeutics Corporation | $16.06 | 2025 | Tyvaso |
| Kiniksa Pharmaceuticals International, Plc | $16.00 | 2024 | Arcalyst |
| Lundbeck LLC | $15.21 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $14.59 | 2023 | Arcalyst |
| Astellas Pharma US INC | $13.89 | 2022 | |
| Amarin Pharma, INC. | $11.69 | 2021 | |
| Lemaitre Vascular, INC. | $10.75 | 2023 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Meade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.